Human Bcl-2 antisense therapy for lymphomas.
Cotter
F E
FE
Division of Cancer Biology, Institute of Child Health, London, UK. f.cotter@ich.ucl.ac.uk
Waters
J
J
Cunningham
D
D
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D017321:Clinical Trials, Phase I as Topic; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000235:genetics; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000235:genetics; D051379:Mice; D016513:Mice, SCID; D016376:Oligonucleotides, Antisense / Q000009:adverse effects / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000235:genetics; D012074:Remission Induction; D013873:Thionucleotides / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016376:Oligonucleotides, Antisense; D019253:Proto-Oncogene Proteins c-bcl-2; D013873:Thionucleotides; C408162:oblimersen